中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2011年
15期
2068-2069
,共2页
脑血管意外%硫酸镁
腦血管意外%硫痠鎂
뇌혈관의외%류산미
Cerebrovascular Accident%Magnesium sulfate
目的 探讨硫酸镁对急性缺血性脑卒中患者的神经保护作用。方法 采用髓鞘碱性蛋白量化分析方法,分析急性缺血性脑卒中患者硫酸镁治疗前后血清髓鞘碱性蛋白水平变化的幅度,并与对照组对比。结果 治疗组20例患者治疗前第1天血清髓鞘碱性蛋白平均水平为(8.3±2.5) μg/L,治疗后第10天为(4.2±1.7) μg/L;对照组20例患者治疗前第1天血清髓鞘碱性蛋白平均水平为(8.0±3.0)μg/L,治疗后第10天为(6.0±1.4) μg/L。两组患者治疗前后血清髓鞘碱性蛋白水平变化幅度的差异具有统计学意义(t=1.231,P=0.041)。结论 硫酸镁可显著降低急性缺血性脑卒中患者血清髓鞘碱性蛋白的水平,具有神经保护作用。
目的 探討硫痠鎂對急性缺血性腦卒中患者的神經保護作用。方法 採用髓鞘堿性蛋白量化分析方法,分析急性缺血性腦卒中患者硫痠鎂治療前後血清髓鞘堿性蛋白水平變化的幅度,併與對照組對比。結果 治療組20例患者治療前第1天血清髓鞘堿性蛋白平均水平為(8.3±2.5) μg/L,治療後第10天為(4.2±1.7) μg/L;對照組20例患者治療前第1天血清髓鞘堿性蛋白平均水平為(8.0±3.0)μg/L,治療後第10天為(6.0±1.4) μg/L。兩組患者治療前後血清髓鞘堿性蛋白水平變化幅度的差異具有統計學意義(t=1.231,P=0.041)。結論 硫痠鎂可顯著降低急性缺血性腦卒中患者血清髓鞘堿性蛋白的水平,具有神經保護作用。
목적 탐토류산미대급성결혈성뇌졸중환자적신경보호작용。방법 채용수초감성단백양화분석방법,분석급성결혈성뇌졸중환자류산미치료전후혈청수초감성단백수평변화적폭도,병여대조조대비。결과 치료조20례환자치료전제1천혈청수초감성단백평균수평위(8.3±2.5) μg/L,치료후제10천위(4.2±1.7) μg/L;대조조20례환자치료전제1천혈청수초감성단백평균수평위(8.0±3.0)μg/L,치료후제10천위(6.0±1.4) μg/L。량조환자치료전후혈청수초감성단백수평변화폭도적차이구유통계학의의(t=1.231,P=0.041)。결론 류산미가현저강저급성결혈성뇌졸중환자혈청수초감성단백적수평,구유신경보호작용。
Objective To explore the neuroprotective effect of magnesium sulfate in tretment of patients with cerebral ischemic stroke. Methods 40 patients with cerebral ischemic stroke were selected and randomly divided into experimental group(20 cases) and control group(20 cases). Among those two groups,the magnesium sulfate therapeutic measure was carried out in the experimental group and the control group was treated without magnesium sulfate. The difference rangeability of level of serum myelin basic protein pre and pro-therapy of both groups was compared. Results For the experimental group, the mean level of serum myelin basic protein in the first day pre-therapy was (8.3 + 2.5) μg/L, and (4.2 ± 1.7) μg/L in 10 days pro-therapy. the csrtrol group was ( 8.0 ± 3.0) μg/L for tite first day pre-therapy,and (6.0 ± 1.4) μg/L in 10 days pro-therapy. The difference rangeability of level of serum myelin basic protein pre and pro-therapy of both groups had statistical significance, compared with the controlled group,the experimental group had lower level of serum myelin basic protein ( t = 1. 231, P = 0. 041 ).Conclusion Magnesium sulfate could significantly decrease the serum level of myelin basic protein for patients with cerebral ischemic stroke,which irdicate that the magnesium sulfate should have neuroprotective effect on patients with cerebral ischemic stroke.